PT904273E - Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2 - Google Patents

Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2

Info

Publication number
PT904273E
PT904273E PT97907237T PT97907237T PT904273E PT 904273 E PT904273 E PT 904273E PT 97907237 T PT97907237 T PT 97907237T PT 97907237 T PT97907237 T PT 97907237T PT 904273 E PT904273 E PT 904273E
Authority
PT
Portugal
Prior art keywords
pyrazazyl
meshlate
benzisoyzazol
ziprasidone
ona
Prior art date
Application number
PT97907237T
Other languages
English (en)
Portuguese (pt)
Inventor
Frank R Busch
Carol A Rose
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT904273E publication Critical patent/PT904273E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97907237T 1996-05-07 1997-03-26 Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2 PT904273E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
PT904273E true PT904273E (pt) 2003-06-30

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97907237T PT904273E (pt) 1996-05-07 1997-03-26 Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2

Country Status (45)

Country Link
US (1) US6110918A (enExample)
EP (1) EP0904273B1 (enExample)
JP (1) JP3102896B2 (enExample)
KR (1) KR100333214B1 (enExample)
CN (1) CN1092658C (enExample)
AP (1) AP838A (enExample)
AR (1) AR007003A1 (enExample)
AT (1) ATE236902T1 (enExample)
AU (1) AU730856C (enExample)
BG (1) BG63601B1 (enExample)
BR (1) BR9708932A (enExample)
CA (1) CA2252895C (enExample)
CO (1) CO4940465A1 (enExample)
CZ (1) CZ289216B6 (enExample)
DE (1) DE69720719T2 (enExample)
DK (1) DK0904273T3 (enExample)
DZ (1) DZ2221A1 (enExample)
EA (1) EA001180B1 (enExample)
EG (1) EG24401A (enExample)
ES (1) ES2192264T3 (enExample)
GT (1) GT199700042A (enExample)
HN (1) HN1997000040A (enExample)
HR (1) HRP970235B1 (enExample)
HU (1) HU229057B1 (enExample)
ID (1) ID17504A (enExample)
IL (1) IL126590A (enExample)
IS (1) IS2301B (enExample)
MA (1) MA26427A1 (enExample)
ME (1) ME00901B (enExample)
MY (1) MY128051A (enExample)
NO (1) NO312513B1 (enExample)
NZ (2) NZ508303A (enExample)
OA (1) OA10908A (enExample)
PL (1) PL188164B1 (enExample)
PT (1) PT904273E (enExample)
SI (1) SI0904273T1 (enExample)
SK (1) SK282674B6 (enExample)
TN (1) TNSN97073A1 (enExample)
TR (1) TR199802241T2 (enExample)
TW (1) TW427989B (enExample)
UA (1) UA47467C2 (enExample)
UY (1) UY24543A1 (enExample)
WO (1) WO1997042190A1 (enExample)
YU (1) YU49398B (enExample)
ZA (1) ZA973875B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
PT985414E (pt) * 1998-05-26 2004-01-30 Pfizer Prod Inc Metodo de tratamento de glaucoma e retinopatia isquemica
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
CZ20023860A3 (cs) * 2000-06-02 2004-01-14 Pfizer Products Inc. S-Methyldihydroziprasidon pro léčení psychických a očních poruch
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
JP2007522095A (ja) * 2003-05-16 2007-08-09 ファイザー・プロダクツ・インク ジプラシドンを用いた不安の治療
MXPA05012391A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
KR20080022595A (ko) * 2003-06-03 2008-03-11 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
AU2004268663B2 (en) * 2003-09-02 2010-12-09 Pfizer Products Inc. Sustained release dosage forms of ziprasidone
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005061493A2 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
EP1720867B1 (en) * 2004-02-27 2009-12-09 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
KR20000010822A (ko) 2000-02-25
YU17397A (sh) 2000-10-30
AR007003A1 (es) 1999-10-13
SK150598A3 (en) 2000-03-13
JP3102896B2 (ja) 2000-10-23
ME00901B (me) 2005-11-28
IS4878A (is) 1998-10-23
IL126590A0 (en) 1999-08-17
DZ2221A1 (fr) 2002-12-03
NO312513B1 (no) 2002-05-21
CZ289216B6 (cs) 2001-12-12
KR100333214B1 (ko) 2002-06-20
MY128051A (en) 2007-01-31
NZ332219A (en) 2005-02-25
SI0904273T1 (en) 2003-08-31
WO1997042190A1 (en) 1997-11-13
HRP970235B1 (en) 2002-08-31
CO4940465A1 (es) 2000-07-24
AU1936897A (en) 1997-11-26
BG63601B1 (bg) 2002-06-28
CA2252895C (en) 2002-08-20
HRP970235A2 (en) 1998-06-30
ID17504A (id) 1998-01-08
PL188164B1 (pl) 2004-12-31
HUP9902808A2 (hu) 2000-03-28
IL126590A (en) 2001-11-25
TW427989B (en) 2001-04-01
CA2252895A1 (en) 1997-11-13
TR199802241T2 (enExample) 1999-02-22
NO985193D0 (no) 1998-11-06
HUP9902808A3 (en) 2000-04-28
PL329880A1 (en) 1999-04-12
BG102893A (en) 1999-09-30
UY24543A1 (es) 2000-09-29
ZA973875B (en) 1998-11-06
CZ349498A3 (cs) 1999-09-15
UA47467C2 (uk) 2002-07-15
AP9700978A0 (en) 1997-07-31
ATE236902T1 (de) 2003-04-15
JPH11509865A (ja) 1999-08-31
IS2301B (is) 2007-10-15
NZ508303A (en) 2001-07-27
MA26427A1 (fr) 2004-12-20
GT199700042A (es) 1998-10-02
CN1216990A (zh) 1999-05-19
EA199800909A1 (ru) 1999-04-29
OA10908A (en) 2001-10-26
HK1017893A1 (en) 1999-12-03
BR9708932A (pt) 1999-08-03
DE69720719T2 (de) 2003-11-06
AP838A (en) 2000-05-03
AU730856B2 (en) 2001-03-15
EG24401A (en) 2009-04-29
HU229057B1 (en) 2013-07-29
HN1997000040A (es) 1997-06-05
ES2192264T3 (es) 2003-10-01
DK0904273T3 (da) 2003-07-07
TNSN97073A1 (fr) 2005-03-15
EA001180B1 (ru) 2000-10-30
SK282674B6 (sk) 2002-11-06
EP0904273B1 (en) 2003-04-09
EP0904273A1 (en) 1999-03-31
CN1092658C (zh) 2002-10-16
NO985193L (no) 1998-11-06
YU49398B (sh) 2005-11-28
US6110918A (en) 2000-08-29
DE69720719D1 (de) 2003-05-15
AU730856C (en) 2001-11-15

Similar Documents

Publication Publication Date Title
PT904273E (pt) Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2
PT918772E (pt) Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2
NO2005009I1 (no) Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
DK0965343T3 (da) Ziprasidonformuleringer
DE69713474D1 (de) Wegwerfhöschen
DE69835847D1 (de) Wegwerfhöschen
ATE229795T1 (de) Hautverträgliche handreiniger, insbesondere grobhandreiniger
DE69709547D1 (de) Wegwerfüberziehunterhose
PT1246816E (pt) Derivados de fenilpiperazina substituidos sua preparacao e utilizacao
DE69718786D1 (de) Benzoxazinone als dopamine -d4- rezeptor-antagonisten
ATE219067T1 (de) Substituierte (2-(1-piperazinyl)ethoxy)methyl- derivate
DE59808461D1 (de) Oxazolidinone als 5-ht2a-antagonisten
ZA200108718B (en) Thiazolidinedione derivative and its use as antidiabetic.
ATE277901T1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
PT1173436E (pt) Derivado de tiazolidinodiona e sua utilizacao como antidiabetico
BR9911178B1 (pt) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos
PT1173437E (pt) Derivado de tiazolidinodiona e sua utilizacao como antidiabetico
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
FI972307A0 (fi) 2-(2,3,5,6-tetrafluori-4-pyridyyli)-1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ES1042364Y (es) "pañal perfeccionado".
UA3423S (uk) Газета "інтерфейс"
KR960033326U (ko) 농사용 햇빛 가리개
ES1044909Y (es) "foco perfeccionado"
BR7700910U (pt) Lixeira descartável
ES1034274Y (es) Servilleta perfeccionada.